

ISSN 3009-3848
ISSNe 3009-383X

Oncology Insights

Official Journal of the Serbian Association for Cancer Research



ISSN 3009-3848
ISSNe 3009-383X

ONCOLOGY INSIGHTS

Official Journal of
the Serbian Association for Cancer Research

Belgrade, Serbia
October, 2023

ONCOLOGY INSIGHTS

Official Journal of the Serbian Association for Cancer Research
Publishing annually

Publisher

Serbian Association for Cancer Research
Belgrade, Serbia

Editor-in-Chief

Dr Milena Čavić

Associate Editors

Dr Milica Pešić, Dr Ivana Z. Matić

Managing Editor

Dr Ana Damjanović Veličković

Technical Editors

Dr Marija Đorđić Crnogorac, Dr Milica Nedeljković

Editors

Dr Radmila Janković, Dr Marko Radulović, Prof. Katarina Zeljić, Dr Ana Krivokuća, Prof. Chiara Ambrogio, Dr Thomas Mohr, Prof. Engin Ulukaya, Prof. Vilma Petrikaite, Prof. Konstantinos Dimas, Dr Cristina Xavier, Dr Remond Fijneman, Prof. Ieronymos Zoidakis, Dr Sergi Castellvi-Bel, Dr Petar Ozretic, Prof. Sonja Levanat

Editorial Council

Dr Ana Đurić, Dr Marko Radulović, Dr Radmila Janković, Prof. Katarina Zeljić, Dr Lidija Todorović

Lector/Corrector

Jana Stefanović

Editorial Office

Serbian Association for Cancer Research

Printed by:

Connect Online Studio
Ćirila i Metodija 2a
Belgrade, Serbia

CIP - Каталогизacija y publikaciji
Narodna biblioteka Srbije, Beograd

616-006-08

ONCOLOGY Insights : official Journal of the Serbian
Associaton for Cancer Research / editor in chief Milena Čavić. -
[Štampano izd.]. - 2023, no. 1- . - Belgrade : Serbian Associaton
for Cancer Research, 2023- (Belgrade : Connect Online Studio). - 30 cm

Godišnje. - Drugo izdanje na drugom medijumu:

Oncology Insights (Online) = ISSN 3009-383X

ISSN 3009-3848 = Oncology Insights (Štampano izd.)

COBISS.SR-ID 125366281

CONTENTS

ONCOLOGY INSIGHTS INFO	I
SDIR6 CONGRESS INFO	III
LEGACY INSIGHTS	1
The foundation of the Serbian Association for Cancer Research	2
SDIR evolution: important steps from 2016 to 2022.	5
FUTURE HORIZONS IN CANCER	7
The importance of sex as a biological variable in cancer research.	8
The Role of Microbiota in Cancer Patients	16
PROCEEDINGS BOOK	23
PLENARY LECTURES	25
Unconventional approaches to the treatment of cancer	25
Targeting KRAS: achievements and drawbacks	25
INVITED LECTURES	26
Discovery of novel HDAC inhibitors for therapy of triple-negative breast cancer – preclinical study	26
Estrogen Receptor Beta promoter methylation as a possible biomarker in breast cancer	26
A new approach to the design of metal-based antineoplastic drugs.	27
Approaches to targeting cancer cell resistances in preclinical research	28
Small hydrophobic molecules in multi-targeted cancer therapy: disruption of plasma membrane and mitochondrial functions	30
Good cop-bad cop: different roles of hsa-miR-93-5p in colorectal cancer	31
Network based approaches in cancer research- chances and challenges	34
Tackling omics research in pathology in a low-budget setting	34
Sex as a biological variable in preclinical melanoma research	35
The importance of adequate molecular diagnostics in the era of precision oncology – focus on lung cancer	36
High-throughput screening of multidrug-resistance markers in non-small cell lung carcinoma patient-derived cells – contribution to personalized treatment.	37
Circulating cytokines as potential biomarkers of disease progression in BRAFwt metastatic melanoma patients receiving anti-PD-1 therapy	40
Targeting chitinase 3-like 1 for the treatment of pancreatic cancer	42
Establishment of a first cancer Biobank at the Institute for Oncology and Radiology of Serbia – advantages, challenges and future perspectives	44
Advancing reversible immunocapture toward scalable purification of extracellular vesicles	45
Dying of cancer cells feeds the others to create more aggressive tumor	46
The role of Hedgehog signaling pathway in plasticity, stemness and resistance of melanoma.	47

What is new in care of Adolescents and Young Adults, AYA with cancer.	49
Control of IFN- γ Responsiveness and Metastatic Potential in Melanoma by GSTA4	50
MicroRNAs – biomarker properties in prostate cancer.	52
Significance of molecular diagnostics in therapy of chronic lymphocytic leukemia.	54
ORAL PRESENTATIONS.	57
The PDK-1 inhibitor GSK2334470 induces cell death and G1 cell cycle arrest in human pancreatic cancer cells	57
Suppressor Effects of The Mixed Ligand Platinum (II) Saccharinate Complexes (<i>trans</i> -[Pt(sac) ₂ (PPh ₃) ₂] and <i>trans</i> -[Pt(sac) ₂ (PPh ₂ Cy) ₂]) on <i>In Vitro</i> And <i>In Vivo</i> Angiogenesis	57
All-trans retinoic acid activities in Merkel cell carcinoma: implication of the retinoic gene signature	58
Predicting response to chemoradiotherapy in locally advanced rectal cancer using MRI-based radiomics features	59
Transcriptomic profiling of the early stage squamous cell lung cancer	59
The role of p53 family in melanoma development and therapy resistance	60
The anticancer effects of triterpene saponin deglucocyclamine isolated from <i>Cyclamen hederifolium</i>	61
The effect of diiron thiocarbonyl complex on tumor cells of different grade.	61
The effects of cisplatin-ibuprofen conjugate free and immobilized in mesoporous nanostructured silica on the change of morphology of mouse melanoma cells, and antitumor potential <i>in vivo</i>	62
Role of Claudins 3, 4 and 7 in Triple Negative Breast Cancer progression.	63
Impairment of cystatin F activation can increase the cytotoxicity of NK cells.	63
Cisplatin-Killed Cells as a Preferable Method for Generating Tumor Cell-Based Vaccines.	64
Modes of Activity and Prognostic Significance of the Hedgehog-Gli Signaling Pathway in Prostate Cancer.	64
Platelet-released factors boost proliferation of multiple myeloma cells and changes in bone marrow stroma with implications of NF κ B pathway involvement	65
<i>In vitro</i> anticancer activity of kaempferol-derived flavonoids against pancreatic adenocarcinoma.	66
Amassing a treasure trove for drug repurposing using chemoproteomics.	66
Characterization of heterogeneity of cancer-associated fibroblasts isolated from PDAC patients	67
Exploring the anticancer activity of essential oil of <i>Satureja montana L.</i> from Montenegro	67
POSTER PRESENTATIONS.	69
A pilot study of the association between variants rs25487 of <i>XRCC1</i> gene, rs1801320 of <i>RAD51</i> gene, and rs13181 of <i>ERCC2</i> gene and acute toxicity of radiation therapy after radical prostatectomy in patients with prostate cancer	69
Overview and data management of gastropancreatic oncology biobank sample and data collection.	69
Detection of resistant <i>EGFR</i> T790M mutation from liquid biopsy samples of patients with advanced non-small cell lung cancer: comparison of qPCR and dPCR detection methods.	71
Histomics: Bridging Radiomics and Histopathology Towards Advancing Prognostication of Breast Cancer Metastasis	71
Effects of promoter methylation and mutation on <i>BRCA1/2</i> expression in ovarian cancer.	74
Ultra-short cfDNA fragment detection during systemic therapy of advanced-stage colorectal cancer	75

Comparison of variant calling tools for mutation analysis of <i>BRCA1</i> and <i>BRCA2</i> genes in patients with epithelial ovarian cancer	76
Expression and heteromerization of adenosine A2A and dopamine D2 G protein-coupled receptors in neuroendocrine tumors of the lung	76
Detection of viral proteins in locally advanced rectal cancer patient samples by mass spectrometry – predictive potential for response to neoadjuvant chemoradiotherapy.	77
Prognostic Value of Combined Hematological/Biochemical Indexes and Tumor Clinicopathologic Features in Colorectal Cancer Patients—A Pilot Single Center Study	78
The Polymorphisms of Genes Encoding Antioxidant Enzymes Modulate the Risk for Testicular Germ Cell Tumor.	79
Complementarity of miR-203a-3p and ETS-1 sequences may influence aggressiveness of papillary thyroid carcinoma.	79
Characterization of nischarin expression in pancreatic ductal adenocarcinoma	80
Expression profile of CD81 gene transcripts in colorectal cancer	81
Genetic polymorphisms of enzymes involved in redox homeostasis can influence survival in smokers and overweight patients with prostate cancer	81
Expression of long non-coding RNA HOTAIR in rectal cancer as a potential predictor of response to chemoradiotherapy	82
Prognostic potential of redox status, SLFN11, and PD-L1 in colorectal cancer patients	82
Interleukin-6, a potential plasma biomarker for diagnosis and prognosis of thyroid neoplasms	83
The effect of tyrosine kinase inhibitors in high-grade glioma patient-derived cells	84
The significance of interleukin-8 in hormonally dependent early breast cancer – association with the established parameters ER/PR and HER2	84
Variant rs745430558 in the <i>SMAD4</i> gene promoter as a biomarker for adenocarcinoma of the pancreas	85
Effect of BET inhibitors on cancer stem cells sorted from primary oral cancer cell culture.	85
Precision medicine in gastrointestinal oncology – gemcitabine-based systemic chemotherapy in patients with advanced/metastatic pancreatic carcinoma	86
Precision medicine in gastrointestinal oncology – therapeutic approach in patients with braf mutant metastatic colorectal cancer: a retrospective analysis.	86
Iron metabolism in the prognosis of epithelial ovarian cancer	87
Can serum HER2 testing add prognostic value to routine tissue HER2 analysis for primary breast cancer patients?	87
Prognostic significance of the localization of the primary tumor and HER2-receptor expression in KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy	88
Expression Profile of Sex Hormone Receptors in Head and Neck Cancer: Unraveling Gender Disparities.	88
Circulating cytokine changes in BRAFwt MM patients during anti-PD-1 therapy.	89
Prognostic significance of pathologically detected extramural venous invasion (EMVI) in rectal carcinoma	90
Genomic instability as a prognostic marker in malignant brain cancer	90
Head and neck cancer: single- and two-stage reconstruction	91
Simultaneous <i>EGFR</i> L858R and T790M mutations in treatment-naïve metastatic lung adenocarcinoma: a case study and therapeutic implications	91

Tracing the connection between trace metals and oxidative stress in malignant brain tumors and hydrocephalus . . .	92
Anti-cancer activity of newly synthesized derivatives of nicotinic acid on several monolayer and three-dimensional solid tumor models	92
The effect of <i>Lactobacillus salivarius</i> on AKT-mTOR signaling pathway in normal, dysplastic, and oral cancer cell co-cultures	93
Violacein enhances the cytotoxic effect of commonly used chemotherapeutics on rhabdomyosarcoma cells	94
Anticancer effects of non-toxic repurposed drugs on hamster fibrosarcoma – fast applicable in oncology	94
Potential of Tamoxifen-based Copper(II) Dichloride in Breast Cancer Therapy	95
The mechanism of action of ruthenium compounds on ovarian tumor cells OVCAR-3.	95
Multidrug resistant non-small cell lung cancer cells present collateral sensitivity to platinum-based drugs.	98
Anoikis as a novel mode of shikonin derivatives anticancer action on C6 glioma cells	98
Different mitochondrial response in A549 KRASG12S cells and MCF7 KRAS wild type cells to the treatment with mitochondrial superoxide radicals triggering agent 2-(1-Benzyl-4-piperidinylamino)-4-(4-chlorophenyl)-4-oxo-N-phenylbutyramide (BPCPh)	99
Anticancer activity of diphenyltin(IV) compounds bearing carboxylato N-functionalized 2-quinolones	100
Bismuth ferrite nanoparticles increase ROS production and p62 expression in A375 melanoma and HeLa cells.	100
Stimulation and inhibition of NF- κ B by repurposed drugs – effects on hamster fibrosarcoma.	101
Targeting Tumor pH: The Role of Sodium Bicarbonate in Cancer Treatment	101
Antitumor potential and impact on redox homeostasis of the essential oil of Black pepper (<i>Piper nigrum L.</i>)	102
Antiparasitic drug Ivermectin, a potential anticancer drug.	103
Role of the SALL2 Transcription Factor in Epithelial-Mesenchymal Transition and its Implication in Tumor Malignancy in Colorectal Cancer	103
Cytotoxic activity of extract of <i>Helichrysum plicatum</i> DC. on human cancer cells <i>in vitro</i>	104
The role of ROS in MAPK-dependent autophagy involved in phorbol myristate acetate-induced macrophage differentiation of HL-60 leukemia cells	104
Monitoring of the presence of EGFR-mutated DNA during EGFR-targeted therapy may assist in the prediction of treatment outcome	105
Benefit of immunotherapy administration on overall survival of patients with NSCLC according to real world data analysis	106
INDEX	107




The first number of Oncology Insights includes
PROCEEDINGS BOOK of
THE SIXTH CONGRESS OF THE SERBIAN ASSOCIATION FOR CANCER RESEARCH
with international participation



From Collaboration to Innovation in Cancer Research

2nd – 4th October 2023
Royal Inn Hotel, Belgrade

SDIR-6 ORGANIZER
Srpsko društvo istraživača raka (SDIR)
Serbian Association for Cancer Research (SACR)
www.sdir.ac.rs



oncogenic $\Delta 40p53\beta$ and a decrease in tumor-suppressive TAp73 β . Finally, we have studied the expression profile of the p53/p73 isoforms in a panel of five patient-derived melanoma cell lines that harbor mutations in BRAF and show different sensitivity to BRAFi and/or MEKi. We have found that increased levels of p53 isoforms (p53 α , p53 β , and $\Delta 40p53\beta$) and lower levels of tumor-suppressive TAp73 β isoform could correlate with acquired resistance to BRAFi/MEKi and/or BRAFi targeted therapy. We, therefore, propose that p53 family isoforms can play a role in melanoma cells' aggressiveness and could be a potential marker and target for melanoma therapy.

Keywords: isoforms, melanoma, p53, p73, resistance, targeted therapy

007

The anticancer effects of triterpene saponin deglucocyclamine isolated from *Cyclamen hederifolium*

Milica Pajović¹, Jovana Stanković Jeremić², Sofija Jovanović Stojanov¹, Dejan Gođevac², Milica Pešić¹, Ana Podolski-Renić¹

¹ Institute for Biological Research "Siniša Stanković" – National Institute of the Republic of Serbia, University of Belgrade, Despota Stefana 142, 11060 Belgrade, Serbia

² University of Belgrade – Institute of Chemistry, Technology, and Metallurgy, National Institute of the Republic of Serbia, Njegoševa 12, 11000 Belgrade, Serbia

Background: Following the traditional Serbian use of cyclamen tubers in the treatment of the most aggressive forms of lung cancer, we performed methanolic extraction of fresh tubers of *Cyclamen hederifolium* to isolate and identify bioactive constituents. The triterpene saponin deglucocyclamine (SDGC) was identified as a major constituent of cyclamen extract, and its anticancer effects were studied using a panel of NCI-60 cell lines and primary cell cultures obtained from patients with non-small cell lung cancer (NSCLC). **Material and Methods:** The cyclamen tubers were ground, lyophilized, and extracted with methanol at room temperature with the use of an ultrasonic bath. The part of the methanol extract was further fractionated by dissolving in H₂O and then washed with CH₂Cl₂. The water layer was extracted with n-BuOH. The butanol extract was fractionated by isocratic CC on silica gel with CHCl₃–MeOH–H₂O eluent. This resulted in the isolation of triterpene saponin deglucocyclamine (SDGC, C₅₂H₈₄O₂₂) which was identified using 1D and 2D NMR spectra. SDGC was tested at 10 μ M against a panel of NCI-60 cancer cell lines and then over a concentration range of 0.01–100 μ M using the sulforhodamine B (SRB) assay. SDGC was also tested in the 0.01–10 μ M concentration range against 5 primary patient-derived NSCLC cell cultures (2 stage IB, 2 stage IIA, and 1 stage IIB) using the MTT assay. Cell death analysis was performed in patient-derived NSCLC cells using annexin/propidium iodide staining and flow cytometry. **Results:** SDGC at 10 μ M after 72 h significantly inhibited cell growth of all tested cancer cell lines in the NCI-60 panel. Therefore, SDGC IC₅₀ values were evaluated across the entire NCI-60 panel, ranging from 600 nM to 1 μ M. In patient-derived NSCLC cells, SDGC IC₅₀ values were between 1.3 μ M and 4.6 μ M after 72 h of treatment. SDGC at 10 μ M induced late apoptosis and necrosis, significantly reducing the percentage of viable cells to 40% after 48 h. At the same concentration, cisplatin was ineffective against patient-derived NSCLC cells. **Conclusion:** The triterpene saponin deglucocyclamine (SDGC), whose anticancer effects have not been studied before, showed promising results against NSCLC, melanoma, colon, breast, ovarian, kidney, prostate, and CNS cancer cell lines, as well as patient-derived NSCLC cells. Further more detailed studies of SDGC at the cellular and molecular level are planned. Keywords: anticancer, cyclamen, NCI-60, non-small cell lung carcinoma, patient-derived cell culture

008

The effect of diiron thiocarbyne complex on tumor cells of different grade

Ekatarina Mihajlović¹, Sanja Jelača¹, Lorenzo Biancalana², Lorenzo Chiaverini², Sanja Mijatović¹, Stefano Zacchini³, Fabio Marchetti², Danijela Maksimović-Ivanić¹

¹Department of Immunology, Institute for Biological Research "Siniša Stanković" – National Institute of Republic of Serbia, University of Belgrade, Belgrade, Serbia

²Department of Chemistry and Industrial Chemistry, University of Pisa, Pisa, Italy

³Department of Industrial Chemistry "Toso Montanari", University of Bologna, Bologna, Italy

Background: Iron is an important trace element with a broad range of functions in diverse physiological processes and a tightly regulated metabolism. Over the years, numerous studies have indicated that cancer cells exhibit an iron-seeking phenotype, meaning they have higher demands for iron than healthy cells. This feature may serve as a foundation for a new approach to cancer therapy. In order to develop an anticancer drug with improved efficacy,

higher selectivity and reduced toxicity, a new organo-diiron complex with a bridging thiocarbonyne ligand (FeSDAP) was synthesized. **Material and Methods:** The cytotoxic effect of FeSDAP was investigated on mouse cancer cell lines (B16-F1 low-invasive melanoma, B16-F10 high-invasive melanoma and 4T1 breast cancer), as well as on mouse embryonic fibroblasts (NIH-3T3). For investigation of its mechanism of action, flow cytometry and light microscopy were used. To investigate how 72h long exposure to DMAP *in vitro* affects the potential of B16-F1 and B16-F10 cells to form tumor *in vivo*, respective subcutaneous syngenic models in C57BL/6 mice were used. **Results and Conclusions:** Treatment with FeSDAP decreased viability of all cells after 72 hours, with significantly less potent effect on embryonic fibroblasts compared to cancer cells, suggesting FeSDAP may possess selectivity towards a malignant phenotype. Melanoma cells were almost equally sensitive to the treatment, but more sensitive than breast cancer cells, so both B16-F1 and B16-F10 were selected for further comparative investigation. Treatment with FeSDAP inhibited proliferation of melanoma cells and caused substantial change in their morphology, which was even more pronounced when it comes to B16-F10 cells. After microscopic evaluation, it was shown that melanoma cells went into senescence. Prominent morphological change of B16-F10 cells was caused by transdifferentiation into Schwann Cell-Like Cells. Further investigation of tumorigenic potential of treated melanoma cells in mice showed that the average tumor size in the groups that received treated cells was significantly smaller, suggesting that melanoma cells have persistently reduced potential to form tumor after single *in vitro* treatment with FeSDAP. Ultimately, these results strongly indicate that investigated diiron thiocarbonyne complexes may display a promising antitumor potential that will be investigated in more detail.

Keywords: cell transdifferentiation, cellular senescence, iron compounds, melanoma

009

The effects of cisplatin-ibuprofen conjugate free and immobilized in mesoporous nanostructured silica on the change of morphology of mouse melanoma cells, and antitumor potential *in vivo*

Teodora Komazec¹, Ekatarina Mihajlović¹, Dijana Bovan¹, Sanja Mijatović¹, Ivana Predarska^{2,3}, Evamarie Hey-Hawkins³, Goran N. Kaluđerović², Danijela Maksimović-Ivanić¹

¹Department of Immunology, Institute for Biological Research "Siniša Stanković", National Institute of the Republic of Serbia, University of Belgrade, Belgrade; Serbia

²Department of Engineering and Natural Sciences, University of Applied Sciences Merseburg, Merseburg, Germany

³Faculty of Chemistry and Mineralogy, Institute of Inorganic Chemistry, Leipzig University, Leipzig; Germany

Background: Active contribution of cyclooxygenase enzymes (COX) and their products, in particular prostaglandin E₂, to tumor progression makes this enzyme an attractive target for molecular therapy in cancer. The combination of conventional chemotherapeutic drugs with COX1/2 inhibitors, and further enhancement of their delivery into target tissue can be a highly prospective approach in cancer therapy, especially in advanced stages. Accordingly, a cytostatic and anti-inflammatory drug conjugate was synthesised, as well as its immobilization in mesoporous nanostructured silica SBA-15. Detailed evaluation of the cytotoxic potential and the mechanism of action of this conjugate and the appropriate material on B16 cells was further performed *in vitro* and *in vivo*. **Material and Methods:** Cell viability of B16 melanoma cells was determined by MTT and CV assays. Cell morphology was estimated by hematoxylin–eosin and Oil Red O staining using light microscopy, while changes in the nuclei were validated by PI staining using fluorescent microscopy. Differentiation of melanoma cells was determined by measurement of tyrosinase activity and the presence of melanin. Syngenic C57BL/6 mice model was used for *in vivo* assessment of the tumorigenic potential of B16 cells exposed to free and SBA-15 loaded conjugate *in vitro*, as well as for the evaluation of the antitumor potential of the experimental substances given in the therapeutic regimen. **Results and Conclusion:** Exposure to free or immobilized cisplatin-ibuprofen conjugate decreased the viability of the B16 cell culture while morphology of survived cells was changed. Cytoplasm of enlarged and elongated cells showed intensive granularity with enhanced lipid content and huge irregularly shaped nuclei with prominent heterochromatin foci, all of which indicated senescent state. Increased activity of tyrosinase and the presence of melanin compared to the control, referred to the differentiation of melanoma cells toward primary phenotype. Further inoculation of pretreated B16 cells into C57BL/6 mice showed decreased potential to form tumor in comparison to tumorigenic potential of untreated cells. Additionally, *in vivo* application of free and SBA-15 immobilized conjugate in therapeutic regimen led to statistically significant reduction of tumor volume, with only fewer signs of toxicity compared to cisplatin as positive control. New knowledge about this compound and corresponding materials reflected in their antitumor potential on mouse melanoma cells, which opens numerous possibilities for further research.

Keywords: cell differentiation, cisplatin, ibuprofen, melanoma, nanoparticles, senescence